| Catalog Number | Product | Size | Price | |
|---|---|---|---|---|
| C3001 | Human CLDN18.2/PA-TU 8902 Stable Cell Line | 2 vials | $8000 | Order |
| Catalog Number | C3001 |
|---|---|
| Cell Line Name | Human CLDN18.2/PA-TU 8902 Stable Cell line |
| Accession Number | NP_001002026.1 |
| Host Cell | PA-TU 8902, a human pancreatic adenocarcinoma cell line |
| Quantity | Two vials of frozen cells (1x106 per vial) |
| Culture Medium | DMEM with 10% FBS, 1 ug/ml puromycin |
| Freezing Medium | 90% FBS and 10% DMSO |
| Storage | Liquid nitrogen upon receipt |
| Product Datasheet: | Download PDF |
Detection of human CLDN18.2 expression on human CLDN18.2/PA-TU 8902 stable cells using a monoclonal antibody specific for human CLDN18.2 at two different concentrations(5 and 0.5ug/ml)
Claudin-18 (CLDN18) is a member of a large family of four-span transmembrane proteins called Claudins. These proteins are the essential components of the mammalian tight junctions (TJs) in epithelial cells. Claudin-18 has two splice variants, 18.1 and 18.2. While CLDN18.1 is specifically expressed in the lung tissue, CLDN18.2 expression in normal tissue is more restricted and is only detected in small patches of stomach mucosal. CLDN18.2 expression is elevated in many types of epithelial cancers including stomach, esophagus, pancreatic and ovarian cancers. The expression of CLDN18.2 is not only detected in primary tumors, but also in the metastatic sites. Therefore, CLDN18.2 is an ideal target for monoclonal antibody-based cancer therapies.
Elsasser HP. et al. Structural analysis of a new highly metastatic cell line Pa-Tu 8902 from a primary human pancreatic adenocarcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 64(4):201-7. 1993.
Tureci O. et al. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals. Gene. 481(2): 83-92. 2011.
Sahin U. et al. Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clin. Cancer Res. 14(23):7624-7634. 2008.